{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000038","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-05-12T21:24:38+00:00","discovered_at":"2026-05-12T21:26:01.272138+00:00","generated_at":"2026-05-12T21:26:47.825316+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones","bullets":["Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.","Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.","Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.","VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.","Deal subject to HSR waiting period expiration or termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000038","json":"https://secwatch.observer/filing/0001034842-26-000038.json","markdown":"https://secwatch.observer/filing/0001034842-26-000038.md","text":"https://secwatch.observer/filing/0001034842-26-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/0001034842-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/rigl-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:26:47.825316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2a7d10a959717ddf61f693fdfdce88f94adae38","claim":"RIGEL PHARMACEUTICALS INC entered into Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. valued at $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest (effective 2026-05-11).","evidence_excerpt":"On May 11, 2026, Rigel Pharmaceuticals, Inc. (\"Rigel\" or the \"Company\") entered into a License Agreement (the \"Agreement\") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the \"Licensors\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/0001034842-26-000038-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc."},{"label":"Value","value":"$70 million upfront payment, $15 million transition completion payment, up to $320 million in milest"},{"label":"Effective","value":"2026-05-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}